What is the Market's View on Incyte Corporation (INCY) Stock's Price and Volume Trends Tuesday?

Overall market sentiment has been down on Incyte Corporation (INCY) stock lately. INCY receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Incyte Corporation has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on INCY!

See Full INCY Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With INCY Stock Today?

Incyte Corporation (INCY) stock has fallen -1% while the S&P 500 has gained 0.04% as of 2:56 PM on Tuesday, Nov 28. INCY is lower by -$0.53 from the previous closing price of $52.87 on volume of 860,659 shares. Over the past year the S&P 500 has gained 14.85% while INCY is lower by -32.75%. INCY earned $1.88 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 27.75. To see InvestorsObserver's Sentiment Score for Incyte Corporation click here.

More About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs. Click Here to get the full Stock Report for Incyte Corporation stock.